// April 18, 2024
USP’s commitment to ESG considerations for a healthier, more sustainable world
At the U.S.
At the U.S.
The development of generic versions of innovator medicines is a global public health need.
Interest in innovative vaccines that use messenger ribonucleic acid (mRNA) and viral vectored tec
To help strengthen the pharmaceutical supply chain and guard against potential shortages that can